A deep learning-based radiomics approach to predict head and neck tumor regression for adaptive radiotherapy.

Journal: Scientific reports
Published Date:

Abstract

Early regression-the regression in tumor volume during the initial phase of radiotherapy (approximately 2 weeks after treatment initiation)-is a common occurrence during radiotherapy. This rapid radiation-induced tumor regression may alter target coordinates, necessitating adaptive radiotherapy (ART). We developed a deep learning-based radiomics (DLR) approach to predict early head and neck tumor regression and thereby facilitate ART. Primary gross tumor volume (GTVp) was monitored in 96 patients and nodal GTV (GTVn) in 79 patients during treatment. All patients underwent two computed tomography (CT) scans: one before the start of radiotherapy for initial planning and one during radiotherapy for boost planning. Patients were assigned to regression and nonregression groups according to their median tumor regression rate (ΔGTV/treatment day from initial to boost CT scan). We input a GTV image into the convolutional neural network model, which was pretrained using natural image datasets, via transfer learning. The deep features were extracted from the last fully connected layer. To clarify the prognostic power of the deep features, machine learning models were trained. The models then predicted the regression and nonregression of GTVp and GTVn and evaluated the predictive performance by 0.632 + bootstrap area under the curve (AUC). Predictive performance for GTVp regression was highest using the InceptionResNetv2 model (mean AUC = 0.75) and that for GTVn was highest using NASNetLarge (mean AUC = 0.73). Both models outperformed the handcrafted radiomics features (mean AUC = 0.63 for GTVp and 0.61 for GTVn) or clinical factors (0.64 and 0.67, respectively). DLR may facilitate ART for improved radiation side-effects and target coverage.

Authors

  • Shohei Tanaka
    Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.
  • Noriyuki Kadoya
    Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan. kadoya.n@rad.med.tohoku.ac.jp.
  • Yuto Sugai
    Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.
  • Mariko Umeda
    Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.
  • Miyu Ishizawa
    Department of Radiological Technology, School of Health Sciences, Faculty of Medicine, Tohoku University, Sendai, Japan.
  • Yoshiyuki Katsuta
    Department of Radiology, Takeda General Hospital, Aizuwakamatsu, Japan.
  • Kengo Ito
    RIKEN Center for Sustainable Resource Science, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan; Graduate School of Medical Life Science, Yokohama City University, 1-7-29 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan.
  • Ken Takeda
    Department of Radiological Technology, School of Health Sciences, Faculty of Medicine, Tohoku University, Sendai, Japan.
  • Keiichi Jingu
    Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.